Literature DB >> 28178514

Projection-Target-Defined Effects of Orexin and Dynorphin on VTA Dopamine Neurons.

Corey Baimel1, Benjamin K Lau2, Min Qiao2, Stephanie L Borgland3.   

Abstract

Circuit-specific signaling of ventral tegmental area (VTA) dopamine neurons drives different aspects of motivated behavior, but the neuromodulatory control of these circuits is unclear. We tested the actions of co-expressed lateral hypothalamic peptides, orexin A (oxA) and dynorphin (dyn), on projection-target-defined dopamine neurons in mice. We determined that VTA dopamine neurons that project to the nucleus accumbens lateral shell (lAcbSh), medial shell (mAcbSh), and basolateral amygdala (BLA) are largely non-overlapping cell populations with different electrophysiological properties. Moreover, the neuromodulatory effects of oxA and dyn on these three projections differed. OxA selectively increased firing in lAcbSh- and mAcbSh-projecting dopamine neurons. Dyn decreased firing in the majority of mAcbSh- and BLA-projecting dopamine neurons but reduced firing only in a small fraction of those that project to the lAcbSh. In conclusion, the oxA-dyn input to the VTA may drive reward-seeking behavior by tuning dopaminergic output in a projection-target-dependent manner.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  dopamine; dynorphin; orexin; ventral tegmental area

Mesh:

Substances:

Year:  2017        PMID: 28178514     DOI: 10.1016/j.celrep.2017.01.030

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  39 in total

1.  Central Orexin A Affects Reproductive Axis by Modulation of Hypothalamic Kisspeptin/Neurokinin B/Dynorphin Secreting Neurons in the Male Wistar Rats.

Authors:  Abdolkarim Hosseini; Homayoun Khazali
Journal:  Neuromolecular Med       Date:  2018-09-14       Impact factor: 3.843

Review 2.  Lateral hypothalamic area neuropeptides modulate ventral tegmental area dopamine neurons and feeding.

Authors:  Patricia Perez-Bonilla; Krystal Santiago-Colon; Gina M Leinninger
Journal:  Physiol Behav       Date:  2020-05-31

3.  The number of lateral hypothalamus orexin/hypocretin neurons contributes to individual differences in cocaine demand.

Authors:  Caroline B Pantazis; Morgan H James; Brandon S Bentzley; Gary Aston-Jones
Journal:  Addict Biol       Date:  2019-07-11       Impact factor: 4.280

4.  Short-term high-fat diet primes excitatory synapses for long-term depression in orexin neurons.

Authors:  Victoria Linehan; Lisa Z Fang; Michiru Hirasawa
Journal:  J Physiol       Date:  2017-12-18       Impact factor: 5.182

5.  Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol.

Authors:  Rachel I Anderson; David E Moorman; Howard C Becker
Journal:  Handb Exp Pharmacol       Date:  2018

Review 6.  Opioid and hypocretin neuromodulation of ventral tegmental area neuronal subpopulations.

Authors:  Taylor S Thomas; Corey Baimel; Stephanie L Borgland
Journal:  Br J Pharmacol       Date:  2017-09-26       Impact factor: 8.739

7.  Learned avoidance requires VTA KOR-mediated reductions in dopamine.

Authors:  Mykel A Robble; Mary E Bozsik; Daniel S Wheeler; Robert A Wheeler
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

Review 8.  The hypocretin/orexin system as a target for excessive motivation in alcohol use disorders.

Authors:  David E Moorman
Journal:  Psychopharmacology (Berl)       Date:  2018-03-06       Impact factor: 4.530

Review 9.  Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.

Authors:  Steven J Simmons; Taylor A Gentile
Journal:  Brain Res       Date:  2019-02-20       Impact factor: 3.252

10.  Alpha-melanocyte stimulating hormone increases the activity of melanocortin-3 receptor-expressing neurons in the ventral tegmental area.

Authors:  Katherine Stuhrman West; Chunxia Lu; David P Olson; Aaron G Roseberry
Journal:  J Physiol       Date:  2019-05-26       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.